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ABSTRACT
Objective: To determine which of the changes in synovial
tissue correlates best with clinical response associated
with effective therapy (adalimumab) to facilitate the
planning of future studies with therapeutic agents for
psoriatic arthritis (PsA).
Methods: A total of 24 patients with active PsA were
randomised to receive adalimumab (n=12) or placebo
(n=12) for 4 weeks. Synovial biopsies were obtained
before and after 4 weeks of treatment.
Immunohistochemical analysis was performed to char-
acterise the cell infiltrate, expression of cytokines and
matrix metalloproteinases (MMPs) and vascularity.
Sections were analysed by digital image analysis.
Statistical analysis was performed using covariance
analysis.
Results: The mean Disease Activity Score in 28 joints
(DAS28) after 4 weeks was 1.92 units lower (95%
confidence interval (CI) 1.07 to 2.77) after adalimumab
therapy compared with placebo. Paired pretreatment and
post-treatment synovial samples were available from 19
patients. Many cell types were reduced after adalimumab
treatment compared to placebo. After applying a ranked
analysis of covariance (ANCOVA) model to correct for
baseline imbalances, a significant effect of treatment was
observed on CD3-positive cells: there was a median
reduction of 248 cells/mm
2 after adalimumab versus
placebo treatment (p=0.035). In addition, the expres-
sion of MMP13 was significantly reduced after active
treatment: the integrated optical density (IOD)/mm
2 was
18 190 lower after adalimumab treatment as compared
to placebo (p=0.033).
Conclusion: Adalimumab therapy in PsA is associated
with a marked reduction in T cell infiltration and MMP13
expression in synovial tissue, suggesting that these
parameters could be used as biomarkers that are
sensitive to change after active treatment in small proof
of concept studies in PsA.
Because the synovium is a primary site of
inflammation, there is increasing interest in study-
ing the synovial tissue (ST) of patients with
rheumatoid arthritis (RA) and psoriatic arthritis
(PsA). In addition to the use of synovial biopsies for
diagnostic purposes
12and pathogenetic studies,
34
serial synovial biopsies have been used to evaluate
the effects of novel treatments.
56This approach
has been proposed to screen for therapeutic effects
of novel antirheumatic interventions.
7
The increase in the development of a variety of
new, targeted therapies clearly raises the need for
sensitive biomarkers, which could be used for
selection purposes during the development process.
In RA a decrease in synovial macrophages has been
shown to correlate with clinical improvement.
8–10
No synovial changes were detectable with analysis
of serial synovial samples from patients with RA
who received either placebo or ineffective treat-
ment.
9 11–13 This suggests that analysis of serial
biopsies could be used as a screening method to
test new compounds requiring relatively small
numbers of subjects. The absence of changes in
the ST after treatment would suggest that the
therapy is probably not effective.
To date, only a few studies have been conducted
in PsA evaluating synovial changes after therapy.
These studies were not placebo controlled, with
biopsies taken at different time points and in part
with variable results.
6 14–18 Based on the limited
data available it was hypothesised that an early
decrease in macrophages (or macrophage subsets),
combined with decrease in vascular markers and/or
adhesion molecules, which were observed in some
of these studies, would best predict clinical
response in PsA.
The primary objective of this study was, there-
fore, to investigate the early changes in the ST
alongside clinical response, by using a known
clinically effective therapy (ie, adalimumab 40 mg
subcutaneously every other week),
19 to identify
sensitive biomarkers that may facilitate the plan-
ning of future studies with novel agents to treat
PsA.
PATIENTS AND METHODS
Patients
Patients with PsA fulfilling the ClASsification of
Psoriatic ARthritis (CASPAR) criteria for PsA,
20 21
aged 18–80 years, were included into the study
after written informed consent was obtained.
Patients had to have active disease at time of
enrolment, defined by the presence of at least 2
tender and 2 swollen joints out of the 68 joints for
tenderness and 66 joints for swelling assessed. One
of the swollen joints had to be a knee, ankle or
wrist joint that was accessible for arthroscopy.
Patients were allowed to use concomitant metho-
trexate, which had to be stable for at least 28 days.
They were not allowed to use any other disease-
modifying antirheumatic drugs (DMARDs)
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period was required. Use of non-steroidal anti-inflammatory
drugs was allowed, provided that the dose had been stable for at
least 28 days. Parenteral, intra-articular or oral use of corticos-
teroids within 28 days before enrolment into the study was not
allowed. Topical treatments for psoriasis were not allowed
14 days prior to baseline, with the exception of low potency
(class I) topical steroids to be used on scalp, palms, groin and/or
soles of feet only. Other exclusion criteria were the use of any
biological agent or investigational drug within the previous
6 months and having a history of tuberculosis or a malignancy
in the past 10 years. Infection with HIV, hepatitis B or C virus
was excluded via serological testing. Patients with another
serious infection within 4 weeks before baseline, or a significant
history of cardiac, renal, neurological or metabolic disease were
excluded from the study. Female patients who were pregnant or
breastfeeding were not allowed to enter the study.
Study protocol
This was a randomised, double-blind, placebo-controlled, single
centre study performed at the Academic Medical Center of the
University of Amsterdam. The study protocol was approved by
the Medical Ethics Committee of the institute and all patients
signed informed consent before the start of the study. They had
a complete medical history taken and underwent a full physical
examination, including joint assessment by a rheumatologist
and skin assessment by a dermatologist. Routine clinical
chemistry, haematology and urinalysis assessments were
performed, as well as a chest x ray and purified protein
derivative (PPD) skin test prior to baseline to exclude patients
with (latent) tuberculosis. Eligible patients were included into
the study within 2 weeks after screening, and were seen at
baseline, week 4 and week 12.
Clinical assessment included a 68 joint count for tenderness
and 66 joint count for swelling, a psoriasis area and severity
index (PASI), a subject’s visual analogue scale (VAS) score for
pain, ranging from 0 mm (no pain) to 100 mm (the worst
possible pain), a subject’s and investigator’s global disease
assessment and a Health Assessment Questionnaire (HAQ) for
functional (dis)ability. Furthermore, C-reactive protein (CRP)
levels and erythrocyte sedimentation rate (ESR) were deter-
mined. A blinded, independent assessor performed the clinical
evaluation. The 28-joint Disease Activity Score (DAS28), which
has been shown to discriminate between active drug and
placebo in clinical trials in PsA, was chosen to monitor changes
in clinical disease activity after therapy.
22 23 In addition, the
American College of Rheumatology (ACR) criteria for improve-
ment were assessed.
24
Treatment
Patients were randomised to receive subcutaneous injections
with either adalimumab 40 mg or matching placebo at baseline
(day 1) and day 15 in a 1:1 ratio. After the second arthroscopy
all patients received adalimumab 40 mg every other week.
Arthroscopy
A needle arthroscopy of an actively inflamed joint (knee, ankle,
or wrist) was performed under local anaesthesia in all patients
before treatment and 28 days after initiation of study medica-
tion from the same joint. The procedures for needle arthroscopy
and tissue processing were performed as described previously in
detail.
25 In summary, to minimise sampling error biopsies were
taken from six or more sites of the joint during each
procedure.
26 27 ST biopsy specimens were immediately
embedded in TissueTek OCT (Miles Diagnostics, Elkhart,
Indiana, USA), snap frozen by immersion in methylbutane
(280uC) and stored in liquid nitrogen until further processing.
Before staining, coded ST samples were cut with a cryostat
(5 mm), fixed with acetone and endogenous protease activity
was blocked with 0.3% hydrogen peroxide.
Immunohistochemical analysis
Serial sections were stained with the following antibodies: anti-
CD3 (SK7; BD Biosciences, San Jose, California, USA), anti-CD4
(SK3; BD Biosciences), anti-CD8 (C8/114B; Dako, Glostrup,
Denmark), anti-CD15 (C3D-1; Dako), anti-CD22 (CLB-B-ly/
1,6B11; Sanquin, Amsterdam, The Netherlands), anti-CD38
(HB-7; BD Biosciences), anti-CD55 (clone 67; Serotech, Oxford,
UK), anti-CD68 (EMB11; Dako) and anti-CD163 (5C6 FAT;
Bachem Peninsula Laboratories, San Carlos, California, USA) to
analyse the cell infiltrate. Antibodies against myeloid-related
protein (MRP)8 (8-5C2; BMA Biomedicals, Augst, Switzerland)
and MRP14 (S36.48; BMA Biomedicals) were used to detect
infiltrating monocytes/macrophages in an early stage of
differentiation.
For immunohistochemical analysis of cytokine expression,
interleukin (IL)1b (2D8; Immunokontact, Stockholm, Sweden)
and IL6 (B-E8; Invitrogen, Breda, The Netherlands) were
stained. Furthermore, von Willebrand factor (vWF) (F8/86;
Dako) was used as a marker to detect blood vessels.
Additionally, the expression of matrix metalloproteinase
(MMP)3 (MAB1339; Bio-Connect, Huissen, The Netherlands)
and MMP13 (VIIIA2; Oncogene, Cambridge, Massachusetts,
USA) was determined.
Sections with non-assessable tissue, defined by the absence of
an intimal lining layer, were excluded from analysis. Staining
for cellular markers was performed using a three-step immuno-
peroxidase method as previously described.
28 For the determina-
tion of cytokine expression, biotinylated tyramine (BT) was
used for amplification after incubation with the secondary
antibody and incubation with streptavidin–horseradish perox-
idase (HRP) conjugate was followed by detection with
aminoethylcarbazole (AEC), as previously described.
29 30 For
control sections, the primary antibodies were omitted or
irrelevant antibodies were applied.
Digital image analysis
After immunohistochemical staining, all sections were coded
and randomly analysed by computer-assisted digital image
analysis (DIA). For all markers, 18 high-power fields were
analysed. CD68 and CD163 expression (macrophage markers)
were analysed separately in the intimal lining layer and the
synovial sublining. The images of the high-power fields were
analysed using the Qwin analysis system (Leica, Cambridge,
UK), as described in detail previously.
31 32
Statistical analysis
SPSS for Windows (V 12.0.2; SPSS, Chicago, Illinois, USA) was
used for statistical analysis. Baseline characteristics between the
two groups were compared using a Student t test for normal
distributed data and a Mann–Whitney U test for variables with
a very skewed distribution. Correlations of changes in clinical
parameters and immunohistochemical markers were analysed
with Spearman rank correlation. Additionally, each of the end
points was analysed using an analysis of covariance model
(ANCOVA) after rank transformation to correct for baseline
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33 The model included terms for treatment as a fixed
effect and the baseline measurement as a covariate. The aim
was to assess the treatment difference.
RESULTS
Demographic features
A total of 24 patients (15 men, 9 women) were included in the
trial, 12 patients were randomised to receive adalimumab and
12 placebo treatment. The mean age was 42.8 (range 21–61)
years for the patients in the adalimumab group and 47.2 (25–78)
years in the placebo group (table 1). The mean PsA disease
duration was comparable in both groups. Concomitant metho-
trexate was used by seven patients in the adalimumab group
and five patients in the placebo group in a comparable dose
(mean 18.2 mg/week and 19.0 mg/week, respectively). None of
the patients had used tumour necrosis factor (TNF) inhibitors in
the past. Most patients (n=16) had polyarticular involvement
according to the Moll and Wright classification,
34 a minority had
an oligoarticular phenotype (n=7) or predominantly distal
interphalangeal involvement (n=1). Two of the patients with
polyarticular disease also had axial involvement. The PsA
phenotypes were not equally distributed between the 2 groups,
with the placebo group harbouring more patients with
polyarticular disease than the adalimumab group (10 versus
6). Despite this difference, the patient groups were comparable
with regard to disease activity markers, such as CRP and
DAS28.
All patients received the two injections with study medica-
tion according to the protocol. Overall study medication was
well tolerated. No infections other than common cold were
reported in the 4-week study period. One patient in the placebo
group complained of more pain in her ankle after the first
arthroscopy, but could undergo the second arthroscopy.
Clinical response
As anticipated, a markedly positive effect of adalimumab
treatment was seen on the DAS28,
23 which was 1.92 units
lower compared with placebo after 4 weeks of treatment (95%
confidence interval (CI) 1.07 to 2.77, p,0.001) (fig 1). The mean
(SD) DAS28 decreased from 4.67 (0.98) to 2.87 (1.27) 1 month
after initiation of adalimumab therapy. This improvement was
not seen in the placebo group, where the mean DAS28 was 5.07
(1.29) before versus 5.20 (1.31) after treatment. After 4 weeks of
treatment, 11 of the adalimumab patients fulfilled the European
League Against Rheumatism (EULAR) criteria for clinical
response
23 35 (6 patients were good and 5 were moderate
responders), versus 0 in the placebo group. Clinical improve-
ment was sustained at week 12, when all 12 adalimumab-
treated patients fulfilled the EULAR criteria for clinical response
(7 good and 5 moderate responders). Based on the 68 tender
joint count and 66 swollen joint count an ACR20 response for
improvement
24 was observed in 5 patients after 4 weeks of
adalimumab treatment (of which 4 also fulfilled the ACR50
response criteria), but in none of the placebo-treated patients.
After 12 weeks of adalimumab treatment 10 patients fulfilled
ACR20 criteria, of which 7 also met the ACR50 response
criteria.
The mean PASI score after 4 weeks of adalimumab treatment
was 2.61 points lower compared to placebo (95% CI 20.08 to
5.30, p=0.056). The mean PASI decreased from 5.89 (4.25) to
4.01 (2.49) in the adalimumab group, whereas there was a slight
increase in the placebo group from 4.72 (2.55) to 5.45 (4.05).
At 4 weeks the ESR and CRP levels were respectively 58%
(95% CI 30% to 86%, p=0.001) and 57% (95% CI 29% to 84%,
p,0.001) lower after adalimumab treatment than after placebo
treatment. The mean ESR was reduced from 24.2 (21.7) mm/h
to 8.1 (7.5) mm/h after adalimumab treatment, and the mean
CRP from 19.9 (25.7) mg/litre to 2.1 (1.4) mg/litre, whereas
after placebo treatment there was no clear cut change: ESR from
22.4 (18.7) to 19.6 (11.9) mm/h and CRP from 9.9 (9.1) to 9.2
(10.0) mg/litre, respectively.
Immunohistochemical analysis
Paired pretreatment and post-treatment synovial samples from
19 patients were available for analysis. The pretreatment ST
biopsies of three patients did not contain an intimal lining layer
and therefore did not pass the quality control tests. Due to an
unfortunate freezer accident ST biopsies of two other patients
were lost. The remaining 19 paired ST samples were analysed,
10 were in the adalimumab group and 9 in the placebo group.
The results of this analysis are shown in table 2. Table 1 Demographic and clinical features of the 24 patients with
psoriatic arthritis (PsA) enrolled in the study
Adalimumab (n=12) Placebo (n=12)
Age, years 42.8 (21–61) 47.2 (25–78)
No. men/women 9/3 6/6
No. (%) currently receiving MTX 7 (58) 5 (42)
Dose MTX, mg/week 18.2 (10–25) 19.0 (15–25)
PsA disease duration, years 5.5 (0.4–14.1) 8.4 (1.9–18.2)
No. (%) RF positive 2 (17) 1 (8)
No. (%) anti-CCP positive 1 (8) 0
No. (%) erosive 7 (58) 5 (42)
ESR, mm/h 24.2 (4–66) 22.4 (3–66)
CRP, mg/litre 19.9 (2.3–81.6) 9.9 (1.3–26.7)
DAS28 score 4.67 (3.0–5.78) 5.07 (2.21–6.83)
Patient global assessment of
disease activity (VAS 0–
100 mm)
73 (45–94) 62.8 (18–92)
Patient assessment of pain (VAS
0–100 mm)
72.8 (55–91) 67.4 (11–89)
PASI 5.89 (0–14.0) 4.72 (0–7.0)
All values are mean (range) except where indicated otherwise.
CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte
sedimentation rate; MTX, methotrexate; PASI, psoriasis area and severity index; RF,
rheumatoid factor; VAS, visual analogue scale.
Figure 1 Effect of treatment with either adalimumab or placebo on the
individual 28-joint Disease Activity Score (DAS28). A marked reduction
is seen after adalimumab treatment for 4 weeks.
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line for several synovial markers between adalimumab and
placebo groups, as shown in table 2 (adalimumab and placebo
before). Most of these baseline differences were not statistically
significant except for the number of CD8-positive cells, CD163-
positive cells and MMP3 expression, which were significantly
higher in the adalimumab group. A marked reduction was
observed in most cell types after active treatment. The effect
after adalimumab was significant for CD3-positive T cells: there
was a median decrease of 248 cells/mm
2 after adalimumab
compared to placebo treatment. There was clear interindividual
variability, which is a well known phenomenon in patients with
various arthritides including PsA.
43 6 However, on the group
level there was a marked decrease in CD3-positive T cells
(median (standard error (SE)) of the median: 212 (230) cells/
mm
2) in the adalimumab group (fig 2), whereas in the placebo
group there was an increase (36 (33) cells/mm
2). A similar effect
was observed for the two T cell subpopulations: there was a
trend towards a reduction of CD4-positive cells (386 (278) cells/
mm
2) after adalimumab compared to an increase (148 (589)
cells/mm
2) after placebo treatment; and a reduction of CD8-
positive cells (103 (72) cells/mm
2) after adalimumab versus a
small increase (4 (7) cells/mm
2) after placebo treatment.
Following adalimumab treatment there was also a decrease in
the number of CD163-positive cells (resident macrophages) and
CD68-positive macrophages, especially in the synovial sublin-
ing, but these changes did not reach statistical significance,
possibly due to the relatively small number of patients. Similar
changes were observed for MRP8 and MRP14-positive macro-
phages (infiltrating monocytes/macrophages in an early stage of
differentiation). There were also trends towards decreased
infiltration by CD22-positive B cells, CD38-positive plasma
cells and CD15-positive neutrophils after active treatment.
There was a trend towards reduction in the expression of the
vascular marker vWF and the proinflammatory cytokines IL1
and IL6 after treatment with adalimumab as compared to
placebo, but the differences were not statistically significant.
There was considerable reduction of expression of MMP3 and
MMP13 in the adalimumab group as compared to placebo. The
expression of MMP13 was decreased with 9188 (8653) IOD/
mm
2 (median (SE)) after adalimumab treatment as compared to
an increase of 9002 (5469) IOD/mm
2 after placebo. When
ANCOVA was applied to correct for the imbalances at baseline,
it turned out that the baseline measurement had the strongest
effect on change in any parameter tested, but for reduction in
the number of CD3-positive cells and MMP13 expression the
effect of treatment remained significant (p=0.035 for CD3-
positive cells and p=0.033 for expression of MMP13).
Correlation between clinical improvement and changes in
synovial biomarkers
For the cellular markers clinical improvement was strongly
correlated with a decrease in CD3-positive T cells (Spearman
rho=0.644, p=0.003), CD4-positive cells (rho=0.649,
p=0.003) and MRP8-positive macrophages (rho=0.561,
p=0.012) (fig 3), but there was no statistically significant
correlation with changes in other cell types. There was also a
strong correlation between clinical improvement and the
reduction of MMP13 (rho=0.619, p=0.005) (fig 3) and
MMP3 (rho=0.560, p=0.013).
DISCUSSION
This placebo-controlled study with adalimumab was conducted
to address the question which features in PsA ST samples could
be used as a biomarker for clinical efficacy on the group level in
relatively small studies of short duration. The results presented
Table 2 Median values (standard error (SE) of the median) for the synovial biomarkers before treatment and median reduction (SE of the median) after
4 weeks of treatment in each group and p value of the ranked analysis of covariance (ANCOVA) applied
Adalimumab Placebo
ANCOVA
p Value Before Reduction Before Reduction
CD68 total 1927 (133) 435 (197) 835 (516) 2534 (567) 0.31
CD68L 378 (28) 236 (61) 177 (140) 2419 (249) 0.35
CD68SL 1423 (262) 147 (59) 753 (628) 2184 (99) 0.23
CD163 total 1243 (208) 765 (309) 480 (178) 286 (409) 0.67
CD163L 426 (203) 167 (72) 68 (8) 39 (46) 0.15
CD163SL 1081 (155) 674 (265) 468 (206) 256 (389) 0.85
CD3 533 (36) 212 (230) 144 (66) 236 (33) 0.035*
CD4 1130 (265) 386 (278) 184 (21) 2148 (589) 0.084
CD8 177 (103) 103 (72) 27 (7) 24 (7) 0.12
CD15 35 (13) 22 (8) 13 (1) 12 (28) 0.42
CD22 306 (167) 210 (145) 44 (7) 20 (27) 0.89
CD38 15 (11) 4 (1) 4 (1) 1 (1) 0.83
CD55 660 (218) 85 (145) 681 (30) 230 (288) 0.60
vWF 137 853 (42 944) 47 107 (25 755) 87 300 (8092) 238 191 (76 306) 0.37
IL1b 515 740 (200 575) 272 189 (74 412) 620 179 (485 911) 31 219 (134 893) 0.31
IL6 169 164 (181 653) 39 063 (49 052) 38 671 (12 175) 266 403 (125 364) 0.18
MRP8 1483 (1550) 1313 (1644) 396 (139) 223 (233) 0.11
MRP14 3976 (1380) 2814 (2339) 1837 (1360) 489 (247) 0.82
MMP3 247 021 (101 010) 138 679 (99 428) 17 680 (1913) 138 (529) 0.64
MMP13 25 822 (15 822) 9188 (8653) 14 673 (10 350) 29002 (5469) 0.033*
CD68+ macrophages (total), CD68+ macrophages in the intimal lining layer (L) and in the synovial sublining (SL), CD163+ cells (subset of macrophages) (total), CD163+ cells in L
and SL, CD3+ T cells, CD4+ and CD8+ T cells, CD15+ neutrophils, CD22 + B cells, CD38+ plasma cells and CD55+ fibroblast-like synoviocytes are provided as cells/mm
2.
Expression of von Willebrand Factor (vWF), interleukin (IL)1b, IL6, myeloid related protein (MRP)8, MRP14, matrix metalloproteinase (MMP)3, MMP13, are provided as median (SE
of the median) integrated optical density (IOD)/mm
2. Differences before treatment between the groups were statistically significant for CD163+ cells (total, L and SL), CD8+ cells and
MMP3 expression, which were higher in the adalimumab group. After ANCOVA was applied to correct for baseline imbalances, the effect of treatment after 4 weeks was significant
only for the reduction in the number of CD3-positive cells (p=0.035) and MMP13 expression (=0.033)*.
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showing CD3+ T cells (red–brown) in
psoriatic arthritis synovial tissue before
and after treatment with adalimumab
(upper panel left and right) or placebo
(lower panel left and right). Magnification
6200. A marked reduction of the number
of CD3+ T cells was observed after
4 weeks of adalimumab treatment.
Figure 3 Scatter plots showing
individual data points for the correlation
between change in 28-joint Disease
Activity Score (DDAS28, a positive value
represents clinical improvement) on the
y axis and change in biomarker (a positive
value represents a reduction of the
expression) on the x axis after 4 weeks
for CD3-positive cells (rho=0.644,
p=0.003), CD4-positive cells
(rho=0.649, p=0.003), expression of
myeloid-related protein (MRP)8
(rho=561, p=0.012) and matrix
metalloproteinase (MMP)13 (rho=619,
p=0.005).
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particularly associated with a marked reduction in CD3-positive
T cell infiltration and expression of MMP13 in the ST of
patients with PsA 4 weeks after initiation of treatment.
Previous work on synovial biomarkers in patients with PsA
has been mainly limited to open studies, mostly of longer
duration. Open label treatment of 10 patients with PsA with
methotrexate resulted in a decrease in T cells and macrophages
as well as reduced expression of IL8, E-selectin, intercellular
adhesion molecule 1 (ICAM-1) and MMP3 after 6 to 12 months
of treatment.
14 In another study 52 patients with peripheral
arthritis due to spondyloarthritis were included; 16 of these had
PsA.
15 The patients underwent synovial biopsy at baseline and
12 weeks following different treatment regimens (infliximab,
etanercept, sulfasalazine or no DMARD). Clinical improvement
correlated with a decrease in CD163-positive macrophages,
polymorphonuclear cells (PMNs) and MMP3 expression. A
study on the effects of TNF blockade showed in 11 patients
with PsA, who were treated with infliximab (3 mg/kg)
combined with stable methotrexate treatment, a significant
reduction of ICAM-1, vWF and avb3 expression.
17 There was
also a trend towards a reduction of T cells and macrophages.
Similarly, another study demonstrated a decrease in macro-
phage numbers and vascular markers in the synovium of nine
patients with PsA 8 weeks after initiation of infliximab (5 mg/kg)
treatment.
18 A study on the effects of alefacept revealed a
significant decrease in T cell numbers after 4 weeks of treatment,
and a significant reduction of T cells and macrophages after
12 weeks of treatment in 11 patients with PsA.
6 Finally,
experimental treatment with IL10 subcutaneously for 4 weeks
resulted in decreased T cell and macrophage infiltration in the
synovium.
37
The present study was designed to determine which synovial
biomarkers are associated on the group level with active
treatment, identical to the approach that we have previously
described in patients with RA.
8 In RA macrophage numbers
were previously identified as synovial biomarkers associated
with active treatment. These results have been confirmed and
validated in various studies.
91 03 8Of interest, although we did
observe clear trends towards decreased numbers of macrophages
and macrophage subsets after active treatment, analysis of
covariance indicates that in PsA especially the number of CD3-
positive T cells and the expression of MMP13 could be used to
screen for potentially active drugs in small proof of concept
studies of short duration. The results presented here underscore
the important role of T cells in the pathogenesis of PsA,
39
consistent with the observation that specific targeting of T cells
may result in clinical benefit in this disease.
64 0
A potential drawback of this study is the fact that there were
baseline differences—in clinical and synovial variables—
between the adalimumab and placebo group despite randomisa-
tion, which is probably related to the relatively small number of
patients. The ANCOVA model, however, includes the baseline
value for each marker as a covariate, thereby correcting for these
baseline imbalances.
41 Using this model to describe the relation-
ship between clinical improvement and changes in ST, the effect
of treatment was sustained for a reduction of T cells and
MMP13 expression. Another potential limitation of this
exploratory study is related to the high number of synovial
parameters tested and the chance of erroneously reporting
statistical significance in the context of multiple comparisons.
The limited power of our study did not allow a conservative
Bonferroni correction. Of importance, other investigators have
very recently independently confirmed the specific decrease in
CD3+ T cells in the synovium after initiation of TNF blockade
in patients with PsA.
42 Thus, it appears unlikely that the
identification of CD3+ T cells as a key synovial biomarker
associated with active treatment can merely be explained by
chance.
The reduction of synovial inflammation associated with
clinical improvement of the joint and skin after adalimumab
treatment is also consistent with previous reports showing a
decrease in leukocyte numbers (including T cells and macro-
phages), as well as reduced vascularity and expression of
proinflammatory cytokines and MMPs in the synovium of
patients with PsA after infliximab treatment.
15–18 The cellular
changes might be explained in part by changes in cell migration
due to reduced neoangiogenesis and reduced expression of
adhesion molecules and chemokines, as suggested pre-
viously.
14 16 17 43
Analysis of molecular markers in synovial tissue is increas-
ingly used in clinical trials on targeted therapies. With this
approach, tissue specificity is not a problem and examination of
serial biopsy samples can be used to monitor the response in
individual patients and screen for interesting biological effects at
the site of inflammation. This study clearly shows that changes
in T cell numbers and the expression of MMP13 in the
synovium of patients with PsA may be used as biomarkers to
screen for effective therapies during early drug development. It
can be anticipated that future developments will include the use
of more extensive markers of synovial inflammation and joint
degradation as well as the use of panels of biomarkers in serum
and synovial tissue samples.
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